Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | GFER | P55789 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427332 | 0.80 | TLR9 (0.42) | KDM4ESMN1; SMN2HPGDALDH1A1NPC1 | |
| SCHEMBL24427598 | 0.78 | KDM4E (0.42) | KDM4ESMN1; SMN2HPGDMAPK14GCGR | |
| SCHEMBL24427244 | 0.75 | MPL (0.40) | SMN1; SMN2ACHEPARP1 | |
| SCHEMBL24427514 | 0.74 | PDPK1 (0.52) | — | |
| SCHEMBL24427480 | 0.73 | MAPK14 (0.36) | MAPK14ALOX5 | |
| SCHEMBL24428023 | 0.72 | CREBBP (0.37) | KDM4EHPGDALDH1A1MAPTPOLB | |
| SCHEMBL24427251 | 0.72 | MAPK14 (0.39) | KDM4ESMN1; SMN2HPGDMAPK14ALDH1A1 | |
| SCHEMBL17832296 | 0.71 | NOS3 (0.34) | KDM4ESMN1; SMN2HPGDPOLBADORA2A | |
| SCHEMBL24427894 | 0.70 | RPS6KA3 (0.49) | KDM4ESMN1; SMN2HPGDMAPK14GCGR | |
| SCHEMBL24427783 | 0.70 | KDM4E (0.35) | KDM4ESMN1; SMN2HPGDPOLBPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11566027-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20210009586-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10815233-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-27 | — | — | US | disclosed |
| EP-3702357-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20200140435-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10550119-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20190352304-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-11-21 | — | — | US | disclosed |
| US-20170349580-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3231803-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016093285-A1 | DIHYDROINDOLIZINONE DERIVATIVE | 小野薬品工業株式会社 | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349580-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885 |
| US-10815233-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885 |
| US-20190352304-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885 |
| US-20200140435-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885 |
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | TFPI, F2, TFPI2 | KDM4E 414/4885SMN1; SMN2 1935/4885HPGD 11/4885 |
| US-20210009586-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885 |
| US-11566027-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885 |
| US-10550119-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.